



# A Paradigm Shift in the Diagnosis and Treatment of Symptomatic Traumatic Brain Injury.

Mark L. Gordon, M.D. and Andrew Marr  
MILLENNIUM-WARRIOR ANGELS FOUNDATION FOR TBI  
October 1, 2018

# White Paper: A paradigm shift in the diagnosis and treatment of symptomatic Traumatic Brain Injury (aka PTS/PTSD).

Mark L. Gordon, M.D., and SFC Andrew Marr, U.S. Army, (Ret). September 2018. Millennium-TBI Veterans Project, Encino, CA, 91436. USA. For the Department of Defense, Office of the Secretary of Defense.

## Abstract

**T**raumatic brain injury, regardless of its cause or degree of intensity, creates changes in the neurochemistry of the brain secondary to neuroinflammation. Neuroinflammation is the hall-mark of all neurodegenerative diseases, arising from microhemorrhages, axonal dissection, and contusions all providing the catalyst (NFkB) for the release of immune-based cytokines such as IL-1, IL-1b, IL-6 and TNF-alpha. The interaction of these inflammatory cytokines with the molecular chemistry associated with the cell membrane alters cellular function leading to neuronal death. As the cellular content of these neurons is released into the surrounding tissues, free radicals are produced raising the level of oxidative stress, thereby furthering disruption of cell signaling and the brain's regulatory systems.

Many traumas are of the polytrauma-type, inclusive of peripheral and internal injuries, adding to the rapid production of cytokines that pass through the blood brain barrier to activate microglia. Microglia activation provides defensive mechanisms to protect neurons, but as the evolution of injury increases more cytokines, chemokines and leukotrienes are released. At a point in time, the load becomes overwhelming and turns destructive leading to the progressive loss of neurons and thereby, cell-to-cell communication. As more and more of these connections are lost, cognitive and neurobehavioral functionality is eroded leaving the individual with symptomatic-TBI which includes depression, anxiety, obsessive-compulsive behavior, bipolar traits, schizophrenia, Alzheimer's disease, and Parkinsonism.

## Introduction: The Issues

**T**he majority of cases of TBI in civilian and combat-related settings are categorized as "mild," a category based primarily on the characteristics of the acute sequelae following the injury. The criteria for the classification of mild can vary, but the DoD/Department of Veterans Affairs March 2009 Clinical Practice Guideline has adopted the following criteria: (1) brief loss of consciousness (<30 min), (2) brief alteration of consciousness (< 24 hours), (3) posttraumatic amnesia for 0 to 1 days, or (4) Glasgow Coma Score of 13 to 15 (15 = normal), and (5) a normal-appearing brain CT-scan [1]. Nonetheless, over time, many of these individuals develop symptoms referred to as post-concussion syndrome, symptomatic TBI, or post-traumatic stress disorder. When the symptoms become socially disruptive, the individual might seek help from their primary care provider who refers them out for psychiatric evaluation after having performed basic biochemical and hormonal assessments. If a history of TBI is acknowledged, an MRI is performed with nearly 80% of these studies being read as normal [2]. At this point, the presentation is considered 100% neuropsychiatric with medication being offered to control the symptoms of depression, anxiety, insomnia, emotional volatility, lack of libido and cognitive impairment [3].

Neuroinflammation, secondary to neurotrauma (TBI), has been documented to be present 17 years after the initial insult thereby, providing evidence that the process is indolent causing a delayed and progressive presentation of symptomatology in these individuals [4]. Once neurotrauma has occurred, there is release

of immune-based cytokines specifically IL-1, IL-1b, IL-6 and TNFa all known to be associated with neurodegenerative disorders and to pass freely into the brain [5]. The present medical community's strategies for treatment of the sequelae commonly presenting in TBI, does not address these important factors.

Instead, the focus of treatment has been to mask the symptoms with the use of polypharmacy. The consequence of this approach has been several generations of veterans and civilians whose lives have been inextricably altered to the worst. Continued personality issues leading to suicide, persistent depression, isolation, disruption of family, loss of jobs and the incarceration of nearly one-million veterans should be ample enough to acknowledge the fact that we have not provided the best answers [6].

It has been the futility of these accepted modalities of assessment and treatment, that has led the Millennium to look at the science of neuroinflammation and its effects on cognition, mood-disorders, and modulation of neuroinflammation via disruption of the brains molecular chemistry (neurosteroids). We believe that we have a plausible answer:

## **A Solution**

### **A. The Laboratory (Objective Biomarkers)**

**S**tarting in 2004, the Millennium Healthcare Centers, Inc. has developed a simple, cost-effective, reproducible, bio-marker panel that uses standard serum blood tests that address an array of neurohormonal markers [7]. These biomarkers look at the brain's regulation of central (neurosteroids) and peripheral hormones (neuroactive steroids) that can be altered after traumatic brain injury [8,9,10]. Additionally, the accuracy of the laboratory results is enhanced by the use of laboratory technology such as Mass-spectrometry (LC/MS/MS/MS) to improve the accuracy and reproducibility of testing. Furthermore, a key to the success of the Millennium's program has been the implementation of a paradigm shift in the interpretation of the laboratory results. Traditionally, the acceptability of any specific laboratory test result is based upon a set of standardized laboratory ranges. Like a ball kicked for a field goal the results must be above the bar and between the poles. Unfortunately, many results are above the bar but to close to either pole instead of being dead center. Laboratory results that come in a few points above the lowest laboratory range are read as "normal" regardless of the symptomatology of the patient.

In 25 years of practicing Endocrinology and 15 years practicing Neuroendocrinology, the difference between a laboratory result being in the center of the range as opposed to being at the lowest numbers of "normal" are worlds apart in symptomatology. Our greatest outcome results are obtained when the neurosteroids and neuroactive steroids are at their median of the range.

### **B. Neurosteroids and Neuroactive Steroids**

**N**eurosteroids (NS) are endogenous neuromodulators synthesized in the brain from cholesterol that rapidly alter neuronal excitability (in real-time) by binding to membrane receptors, in addition to the induction of gene expression via intracellular steroid receptors. Neuroactive steroids induce significant antidepressant, anxiolytic, anticonvulsant, analgesic and amnesic effects, mainly through interaction with the gamma-amino-butyric type A (GABA<sub>A</sub>) receptor. They also exhibit neuroprotective, neurotrophic and antiapoptotic effects along with the ability to diminish free-radical stress all associated with neurodegenerative diseases [11].

Neuroactive steroids (NAS) are a group of hormones, derived from cholesterol, which represent the steroidal family that passes through the blood-brain barrier to genetically, epigenetically, and biochemically influence the brains functioning [12].

Recognition of the influence of both neurosteroids and neuroactive steroids on brain function and health, has been advancing since the 1980's when Dr. Etienne-Emile Baulieu identified glia cells production of enzymes necessary to metabolize cholesterol down the Pregnenolone cascades to progesterone, cortisol, DHEA, testosterone, DHT, and estrogens [13]. In the past 30 years, the molecular chemistry by which neurosteroids influence and regulate our neuropsychobiology has been increasing at an accelerated rate [14,15,16], while acceptance of the science has been slow to occur.

### **C. Neuroinflammation and Neuropsychiatric Disorders**

**N**europsychiatric disorders including conditions such as schizophrenia, major depressive disorder, and bipolar disorder are generally considered to have a multifactorial pathophysiology including both genetic and environmental factors [17]. The finding of significantly higher levels of inflammatory markers in patients suffering from neuropsychiatric disorders has laid the foundation for understanding the important role that inflammation has in the pathogenesis of these conditions [18,19,20,21]. Patients with depression [22], Schizophrenia, Anxiety, symptomatic TBI (PTSD), bi-polar, obsessive disorder [23] have been shown to present an increase in serum levels of proinflammatory cytokines, such as IL-1, IL-6, IL-8, IL-12, interferon-c and TNF-a [24].

It is the presence of this molecular chemistry, precipitated by neuroinflammation, that is being recognized as the mechanism mediating the onset of a broad range of psychiatric disorders and contributing to non-responsiveness to current therapies [25]. This provides a fundamental understanding for why our treatment of depression as well as other forms of neuropsychiatric disorders are met with resistance and the higher risk of suicide. As long as there is inflammation there cannot be a return to a Neuropermissive environment that fosters reduction of inflammation, return of normal brain chemistry, and the healing of the brain [26].

### **D. Treatment with Nutraceuticals**

**B**ased upon the overwhelming amount of science that already existed, it made sense to approach the treatment of neuroinflammation with a selection of nutraceutical products that have data supporting their ability to modulate inflammation as well as replenish both neurosteroids and neuroactive steroids that were deficient.

Using the results of the biomarker panel, medical and mental health histories, medication response and supplement history, nutrition and exercise history, a treatment protocol was assembled that incorporates nutraceutical products that have a suppressing (down-regulation) effect on NFkB induction and the release of inflammatory cytokines. A few of these products are the tocopherols [27], polyphenols [28], N-acetyl cysteine [29], and eicosanoids [30] each nutraceutical has a wealth of peer-reviewed literature supporting their beneficial effects on traumatic brain injury and neuroinflammation.

### **E. Address the Gut-Brain Relationship/Nutrition**

**I**nflammation arising from the gut under stress, dysbiosis, antibiotic use, or altered immune system functioning generates additional cytokines that readily diffuse into the brain. The use of good nutrition

with emphasis on an anti-inflammatory diet can lower the production of these chemicals while the addition of probiotics can help to heal the damaged gut [ 31].

### **Cost-Effectiveness**

**T**he Congressional Budget Office, responsible for providing budget and economic information to Congress, issued a report in February 2012 titled, “The Veterans Health Administration’s Treatment of PTSD and Traumatic Brain Injury Among Recent Combat Veterans.” The report stated that the average cost per patient (in dollars) for the first year of treatment for all health care provided to overseas contingency operations (OCO) patients by the Veterans Health Administration was \$8,300 for PTSD, \$11,700 for TBI, and \$13,800 for both PTSD and TBI [32]. On average, the cost for the first year of the Millennium’s assessment and treatment which includes the Millennium’s initial bio-marker blood testing, three monitoring blood panels with consults, all physician consultations, and the patient’s personalized treatment protocol is \$7,000. The Millennium’s on average cost in year two and three drops down to \$4,750 and \$3,500, respectively.

### **Experiential Results**

**S**ince 1995, the Millennium has treated patients with hormonal deficiencies noting the improvement in cognitive and mental health. It was not until 2004, when a renaissance in the medical literature suggested that there was a relationship between traumatic brain injury precipitated hormonal deficiencies and the development of neuropsychiatric illnesses. Using this triad, we culled from peer-reviewed literature research that offered a solution to the symptomatology associated with TBI based upon the causation: neuroinflammation.

Translational medicine is based upon the application of bench-research into a clinical setting years before it is brought into mainstream medicine [33,34,35]. The science supporting the application of each of our nutraceutical products has been sitting waiting to be read and applied. In 2004, the Millennium began the process of identifying products which were natural and supported by multiple research sources. As the years advanced, the number of articles grew adding to the wealth of information needed to justify their use in a clinical setting for those individuals experiencing symptomatic TBI.

In 2009, the Millennium evaluated and treated its first active military (JR) who had been exposed to multiple fire-fights, blast trauma, and jarring during his decades in the Green Berets. Using our first neurosteroid/neuroactive steroid assessment panel we provided a treatment protocol that improved his symptoms which allowed him to avoid medical discharge. In 2014, the Millennium began working with Andrew Marr, a medically retired Green Beret, and the co-founder of Warrior Angels Foundation, along with his brother Adam Marr (former Army Aviation Officer). Andrew had been on 13 different medications and used alcohol to “cut the edge” off his emotional lability. Within weeks of his biomarker assessment and treatment, he was no longer on medication or drinking.

Together as the Millennium-Warrior Angels Foundation (MWAFF); we recruited into our project other veterans and active military with symptomatic TBI unchanged or worsened by conventional therapies. Each participant fills out a 23-page intake packet that includes lifetime injuries (civilian and military exposures), subjective behavioral inventory, physical status, nutrition, exercise and drug/medication history before having their biomarker panel performed. Once the results are received, a 4-page report is prepared, and a consult is arranged to review the history, results of labs, and the proposed treatment protocol. The treatment protocol consists of 80-90% nutraceuticals that address inflammation,

suppression of cytokine production, and replenishment of important prohormone while 10% - 20% are prescription medications such as thyroid hormones, estrogen, progesterone, and testosterone. All of the hormones are bio-identical and of plant sources.

Since 2009, we have provided full or partial financial grants to cover program expenses for nearly 300 veterans and/or active military. We also have 6 Vietnam war-era heroes in the population between the ages of 70 and 78 all doing impressively well. Each participant self-monitors their progress with our Monthly Program Questionnaire (MPQ) that looks at psychological, physiologic and physical parameters. Follow-up laboratory testing is performed at 3, 6, and 12 months after starting their treatment protocol. Modification to their initial protocol can be based upon their MPQ responses and their laboratory results.

At present, we are tracking 318 individuals who have had a 62% improvement in less than 6 months. Most if not all have reintegrated into life, their family, work, higher-education, and are off their prescription medications by taking cost-effective and efficient nutraceutical preparations. We have collected both subjective and objective data on over 2300 participants in our program from our offices in Encino California.

### **Recommendation**

**I**t is the goal of the MWAF to provide a network of facilities around the United States that can emulate and provide the standards of evaluation and treatment that the Millennium has worked on for over 15 years. In regard to our military (veterans and active service personnel), we would like to provide to the DoD/VA the information that we used to develop our program. Ultimately, upon acceptance of the science, a pilot program involving a group of veterans suffering with symptomatic TBI (PTSD/CTE) would be enrolled into the project. Outcome results from this trial population would be used to generate publishable articles to further the acceptance of this paradigm in diagnosis and treatment.

Until such time as the pilot program can be initiated, we would offer our data on patient history, laboratory testing, treatment protocols, and outcomes. We believe that the wealth of documented pre- and post-status reports will allow for the pilot program to move forward. Most importantly will be the education of the assigned medical staff to move this and future programs forward.

### **Summary**

**T**he continued loss of American lives secondary to depression and suicide is not abating. Conventional medical wisdom elects to treat the symptoms of a condition that has a clear biochemical causation with medication that just masks the symptoms. Laboratory testing is available to identify the alterations in the brain's neurosteroids which can be replenished while providing a non-toxic treatment protocol to drop the inflammatory cytokines initiated by trauma. The Millennium-Warrior Angels Foundation has been providing such assessment and treatment to almost 300 military and over 2000 civilians with an average improvement in life scores of over 60%. It is time now to look closely at the science that has been available for over 30 years and to start the process of fixing the problem and not just masking it.

## References (additional references available upon request)

- (1) The Management of Concussion/mTBI Working Group. VA/DOD Clinical practice guidelines for management of concussion/mild traumatic brain injury. 2016. <https://www.healthquality.va.gov/guidelines/rehab/mtbi/>
- (2) Review of the Effectiveness of Neuroimaging Modalities for the Detection of Traumatic Brain Injury. *Journal of Neurotrauma* 32:1693–1721. Nov 2015. <https://www.liebertpub.com/doi/10.1089/neu.2013.3306>
- (3) Neuropsychiatric Sequelae of Traumatic Brain Injury. *Psychosomatics* 2000; 41:95–103. <https://biav.net/wp-content/uploads/2017/06/NeuropsychiatricSequelaeTBI.pdf>
- (4) Inflammation after Trauma: Microglial Activation and Traumatic Brain Injury. *Annals of Neurology* 2011; <https://www.ncbi.nlm.nih.gov/pubmed/21710619>
- (5) Military-related traumatic brain injury and neurodegeneration. *Alzheimer's Dement.* 2014 Jun; 10(3 0): S242–S253 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255273/>
- (6) Invisible Wounds of War: Psychological and Cognitive Injuries, Their Consequences, and Services to Assist Recovery 13 Jan 2015 <https://doi.org/10.1176/ps.2009.60.2.273>
- (7) Chapter 6: The Laboratory of TBI. TBI – A Clinical Approach to Diagnosis and Treatment. 2015 May
- (8) Chapter 1: Pathophysiology of hypopituitarism in the setting of brain injury. *Pituitary*. 2012. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170072/>
- (9) Hypothalamic-pituitary Dysfunction following Traumatic Brain Injury and Aneurysmal Subarachnoid Hemorrhage: A Systematic Review *JAMA*. 2007;298(12):1429–1438. <https://jamanetwork.com/journals/jama/fullarticle/208915>
- (10) Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury. *Europe J Endocrinology*. 2006; 154(2):259–65. <https://ej.e.bioscientifica.com/view/journals/eje/154/2/1540259.xml>
- (11) Neurosteroids: trophic effects in the nervous system. *J Soc Biol* 193:285–292; 1999.
- (12) Neurosteroidogenesis today: Novel targets for neuroactive steroid synthesis and action and their relevance for translational research. *J Neuroendocrinol*. 2016 February; 28(2): <https://iris.unito.it/retrieve/handle/2318/1557419/126894/2015PorcuJNe.pdf>
- (13) Astrocytes and Neurosteroids: Metabolism of Pregnenolone and Dehydroepiandrosterone. Regulation by Cell Density. *The Journal of Cell Biology*, Volume 121, Number 1, April 1993 135–143. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2119772/>
- (14) Steroid synthesis and metabolism in the nervous system: Trophic and protective effects. *J. Neurocytology* 29, 307–326. 2000. <https://link.springer.com/article/10.1023/A:1007152904926>
- (15) Neurosteroids: Endogenous Role in the Human Brain and Therapeutic Potentials. *Prog Brain Res*. 2010 ; 186: 113–137. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139029/>
- (16) Neuroactive Steroids are Altered in Schizophrenia and Bipolar Disorder: Relevance to Pathophysiology and Therapeutics. *Neuropsychopharmacology* (2006) 31, 1249–1263. <http://www.nature.com/articles/1300952>
- (17) How to link brain and experience? spatiotemporal psychopathology of the lived body, *Frontiers in Human Neuroscience*, vol.10, 2016. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849214/>
- (18) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction,” *Journal of Psychiatric Research*, V44,#5, pp. 321–330, 2010.
- (19) Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study, *The Amer J of Psychiatry*, V168,#12,2011. <https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2011.11030516>
- (20) Pro-inflammatory cytokines are elevated in adolescent females with emotional disorders not treated with SSRIs. *Journal of Affective Disorders*, V136, N3. 2012. <https://www.sciencedirect.com/science/article/pii/S0165032711005805>
- (21) Neuroinflammation Regulates Cognitive Impairment in Socially Defeated Mice. *Trends in Neurosciences*, vol.39, no.6, pp. 353–355, 2016. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884537/>
- (22) Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *J Psychiatry Res* 41:326–331. 2007. <https://www.ncbi.nlm.nih.gov/pubmed/16870211>
- (23) Cytokines and major depression. *Progress in Neuropsychopharmacology Biol Psychiatry* 29:201–217. 2005. <https://www.sciencedirect.com/science/article/pii/S0278584604002453>
- (24) Modulating Neuroinflammation to Treat Neuropsychiatric Disorders. *Biomedical Res. Intl* vol. 2017. ID 5071786. Pp 1 – 21. <https://www.hindawi.com/journals/bmri/2017/5071786/>
- (25) Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. *Am J Psychiatry* 2016; 173:575–587. <https://ajp.psychiatryonline.org/doi/pdfplus/10.1176/appi.ajp.2016.15091228>
- (26) Chapter 7: The Laboratory of TBI. TBI – A Clinical Approach to Diagnosis and Treatment. 2015 May
- (27) Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. *Free Radical Biol Med*. 2008 March 15; 44(6): 1203–1208. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676174/>
- (28) The Flavonoid Quercetin Inhibits Proinflammatory Cytokine (TNF-Alpha) Gene Expression in Normal Peripheral Blood Mononuclear Cells via Modulation of the NF-kB System. *Clinical and Vaccine Immunology*, Mar. 2006, p. 319–328. <https://cvi.asm.org/content/cdli/13/3/319.full.pdf>

- (29) Efficacy of N-Acetyl Cysteine in Traumatic Brain Injury. Plos One. April 2014. Vol 9., Issue 4., e90617. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989181/>
- (30) **When Brains Collide:** What Every Athlete and Parent Should Know About the Treatment of Concussions and Head Injuries. Austin: Lioncrest Publishing; 2016. Michael D. Lewis MD. (ret. Colonel)
- (31) Principles and clinical implications of the brain–gut–enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009 May; 6(5). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817714/>
- (32) The Veterans Health Administration’s Treatment of PTSD and Traumatic Brain Injury Among Recent Combat Veterans. The Congressional Budget Office. February 2012. <https://www.cbo.gov/publication/42969>
- (33) The Meaning of Translational Research and Why It Matters. JAMA. 2008;299(2):211-213. <https://jamanetwork.com/journals/jama/article-abstract/1149350>
- (34) Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci. 2010 December 1; 31(12): 596–604. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999630/>
- (35) Promoting Translational Research in Medicine through Deliberation. Northwestern University Evanston, IL May 2009.

